Organoid xenograft transplantation into immunodeficient mice was not successful; however, an in vivo xenograft using organoid tissue from a different patient with PDAC harboring a 4-fold HER2 amplification and KRAS G12D mutation was viable and showed markedly reduced tumor volume after T-DXd exposure versus control (Fig 3D). Here, KRAS is linked to neoplasm.